News About: R&D
Wyeth Korea to introduce new version of pneumococcal polysaccharide vaccine from this November
Wyeth Korea said it would launch from this November a new version of 23-valent pneumococcal polysaccharide vaccine (23PS), Prevnar, or heptavalent pneumococcal conjugate vaccine (PCV7) and can be given to younger chil...
Medical adhesives emerging as high value-added item
Stimulated by growing number of patent application and intensive studies by domestic pharmaceutical firms, domestic medical adhesive market has emerged as one of the enticing items in the near future, business sources...
Government unveils 10 technology growth engines
The government said it designated the list of ten technology items, including new biodrugs, that are expected to lead Korea's economic growth, from the August 22 meeting at presidential blue house and 160 representati...
Biosapogen to develop antineoplastic agent containing ingredients of ginseng
Korea Green Cross Sang-A said that its affiliated company Biosapogen, bioventure firm having differentiated gensenoside, is economically producing Rh2 and Rg3, which are contained in a wild ginseng as small amounts, o...
New sustained-release antihypertensive selected as government-funding R&D project
The Small and Medium Business Administration recently announced that a new sustained-release antihypertensive, which has been co-developed by Kolmar Korea and DDSTech, was selected as one of the government-funding R&D...
Domestic pharmaceutical firms to promote R&D new drug projects via foreign exchanges and joint...
Domestic pharmaceutical firms to promote R&D new drug projects via foreign exchanges and joint research
A group of 25 pharmaceutical firms and bioventure companies attended a recent biobusiness and partnering forum...
Tax breaks aim to boost R&D investment
The temporal adoption of an alternative minimum tax rate will spur smaller pharmaceutical firms to spend more R&D investment, the Korea Pharmaceutical Manufacturers Association said recently.
This series of stimulu...
Hospital of Jaseng Oriental Medicine wins USA product patent for Sinvarometin
The Central Disc Center at Hospital of Jaseng Oriental Medicines said it won a U.S. product patient (No. 6,531,582B1) related to Sinvarometin, a novel herbal compound extracted from its Chuna therapy (combinations of ...
Clear definition of new drugs urged
Domestic R&D based pharmaceutical firms have recently contended that more clear definition of new drugs and their license standards need to be re-established, as the current approval of Korean new drugs have been made...
KDRA to implement Technology Road Map for genetic engineering field
The Korea Drug Research Association signed an consignment agreement with the Industrial Technology Corporation of Ministry Commerce, Industry and Energy on June 1st in a bid to undertake the implementation of ...
